Dr. Ed Lavelle graduated with a BSc in Microbiology from University College Galway in 1990 and a PhD in Immunology from the University of Plymouth in 1994. He carried our postdoctoral research at the University of Nottingham on nano and microparticles as vaccine adjuvants. This was followed by further postdoctoral positions at the Rowett Research Institute (Aberdeen) and Trinity College Dublin on vaccine adjuvants and immunomodulators.
He was appointed as a lecturer in Immunology in 2004, senior lecturer in 2012 and Professor in Immunology un 2015 and is a Principal Investigator in the School of Biochemistry and Immunology. His research focuses on the development and mode of action of particulate adjuvants for injectable and mucosal vaccines. The group works closely with a number of Biotech companies and Pharma engaged in vaccine research.
Dr Lavelle is particularly interested in the following areas relating to adjuvant research:
1) Researching particle based vaccine adjuvants to promote enhanced protective immunity against infectious diseases and cancer.
2) Novel oral vaccine delivery systems to promote enhanced mucosal immunity and address challenges relating to maintaining the cold chain. Dr Lavelle’s work in AMBER focuses on the development of innovative oral capsule (SmPill®) systems for oral vaccines. This work is a collaboration with Sigmoid Pharma Ltd, an innovative drug delivery company based in Dublin.
3) The relationship between biomaterial physicochemical characteristics including size, shape and charge and their modulation of innate and inflammatory responses in the host.